Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 16;10(22):5335.
doi: 10.3390/jcm10225335.

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication-A Systematic Review

Affiliations
Review

What We Know about the Long-Term Risks of Hysterectomy for Benign Indication-A Systematic Review

Obianuju Sandra Madueke-Laveaux et al. J Clin Med. .

Abstract

Hysterectomy is the most common treatment option in women with uterine fibroids, providing definitive relief from the associated burdensome symptoms. As with all surgical interventions, hysterectomy is associated with risk of complications, short-term morbidities, and mortality, all of which have been described previously. However, information on the potential long-term risks of hysterectomy is only recently becoming available. A systematic literature review was performed to identify studies published between 2005 and December 2020 evaluating the long-term impact of hysterectomy on patient outcomes. A total of 29 relevant studies were identified. A review of the articles showed that hysterectomy may increase the risk of cardiovascular events, certain cancers, the need for further surgery, early ovarian failure and menopause, depression, and other outcomes. It is important to acknowledge that the available studies examine possible associations and hypotheses rather than causality, and there is a need to establish higher quality studies to truly evaluate the long-term consequences of hysterectomy. However, it is of value to consider these findings when discussing the benefits and risks of all treatment options with patients with uterine fibroids to allow for preference-based choices to be made in a shared decision-making process. This is key to ensuring that patients receive the treatment that best meets their individual needs.

Keywords: adverse events; complications; long-term consequences of hysterectomy; patient engagement; uterine fibroid management; uterine fibroids.

PubMed Disclaimer

Conflict of interest statement

Obianuju Sandra Madueke-Laveaux is a consultant for CooperSurgical, Inc. Ayman Al-Hendy has provided consulting services to AbbVie, Bayer, Myovant, Novartis, and ObsEva, and he is grant funded by the National Institute of Health for fibroid-related research (R01 ES 028615-01, R01 HD 087417, R01 HD 094378, R01 HD 094380, 5U54 MD 007602-32, R01 HD 100367). In addition, he holds a patent for Methods for novel diagnostics and therapeutics for uterine sarcoma (US Pat No. 9,790,562 B2). Amro Elsharoud declares no conflict of interest.

Figures

Figure 1
Figure 1
Cumulative incidence curves for cardiovascular and metabolic conditions in women who underwent hysterectomy with ovarian conservation at 35 years or younger compared with age-matched referent women (stratified analyses). The hazard ratios (HRs) and corresponding 95% confidence intervals were calculated using Cox proportional hazards models with age as the time scale and adjusted using inverse probability weights. Reprinted from Menopause, Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study, 25: 483–492, ©2018, with permission from Wolters Kluwer Health, Inc. [34].
Figure 2
Figure 2
Age-specific rates of first urinary incontinence operation in women in the exposed and unexposed cohorts. Age-specific rates are shown with 95% CIs. Age intervals show attained age during follow-up period. Reprinted from The Lancet, 370, Altman et al., Hysterectomy and risk of stress-urinary-incontinence surgery: nationwide cohort study, 1494–1499, ©2007, with permission from Elsevier [47].

Similar articles

  • The management of uterine leiomyomas.
    Vilos GA, Allaire C, Laberge PY, Leyland N; SPECIAL CONTRIBUTORS. Vilos GA, et al. J Obstet Gynaecol Can. 2015 Feb;37(2):157-178. doi: 10.1016/S1701-2163(15)30338-8. J Obstet Gynaecol Can. 2015. PMID: 25767949
  • The management of uterine leiomyomas.
    Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, Fortier M, Wagner MS; Clinical Practice Gynaecology Committee, Society for Obstetricians and Gynaecologists of Canada. Lefebvre G, et al. J Obstet Gynaecol Can. 2003 May;25(5):396-418; quiz 419-22. J Obstet Gynaecol Can. 2003. PMID: 12738981
  • SOGC clinical practice guidelines. Uterine fibroid embolization (UFE). Number 150, October 2004.
    Society of Obstetricians and Gynaecologists of Canada. Society of Obstetricians and Gynaecologists of Canada. Int J Gynaecol Obstet. 2005 Jun;89(3):305-18. doi: 10.1016/j.ijgo.2005.03.013. Int J Gynaecol Obstet. 2005. PMID: 16001461 Review.
  • SOGC clinical guidelines. Hysterectomy.
    Lefebvre G, Allaire C, Jeffrey J, Vilos G, Arneja J, Birch C, Fortier M; Clinical Practice Gynaecology Committee and Executive Committeee and Council, Society of Obstetricians and Gynaecologists of Canada. Lefebvre G, et al. J Obstet Gynaecol Can. 2002 Jan;24(1):37-61; quiz 74-6. J Obstet Gynaecol Can. 2002. PMID: 12196887 English, French.
  • Management of uterine fibroids: an update of the evidence.
    Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, Lux LJ, Lohr KN. Viswanathan M, et al. Evid Rep Technol Assess (Full Rep). 2007 Jul;(154):1-122. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18288885 Free PMC article. Review.

Cited by

References

    1. Pérez-Lopez F.R., Ornat L., Ceausu I., Depypere H., Erel C.T., Lambrinoudaki I., Schenck-Gustafsson K., Simoncini T., Tremollieres F., Rees M. EMAS position statement: Management of uterine fibroids. Maturitas. 2014;79:106–116. doi: 10.1016/j.maturitas.2014.06.002. - DOI - PubMed
    1. Zimmermann A., Bernuit D., Gerlinger C., Schaefers M., Geppert K. Prevalence, symptoms and management of uterine fibroids: An international internet-based survey of 21,746 women. BMC Women’s Health. 2012;12:6. doi: 10.1186/1472-6874-12-6. - DOI - PMC - PubMed
    1. Maruo T., Ohara N., Wang J., Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum. Reprod. Update. 2004;10:207–220. doi: 10.1093/humupd/dmh019. - DOI - PubMed
    1. Stewart E.A., Cookson C.L., Gandolfo R.A., Schulze-Rath R. Epidemiology of uterine fibroids: A systematic review. BJOG. 2017;124:1501–1512. doi: 10.1111/1471-0528.14640. - DOI - PubMed
    1. Baird D.D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am. J. Obstet. Gynecol. 2003;188:100–107. doi: 10.1067/mob.2003.99. - DOI - PubMed